Uncategorized

May 15 2020

Clinical Trial Outcomes of Recardio’s Dutogliptin Published in the British Journal of Pharmacology

San Francisco, May 15, 2020 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced publication of the outcomes of the Phase 1 clinical trial of its lead candidate dutogliptin. Entitled “Safety, tolerability, pharmacokinetics, and pharmacodynamics of parenterally administered dutogliptin: A prospective dose escalating trial”, the article can be accessed here: https://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.14208

Feb 17 2020

Recardio Completes Interim Analysis of Phase 2 in AMI

San Francisco, February 17, 2020 – Recardio Inc., a clinical stage life science company, announced that it has completed an interim analysis of its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction. Patient recruitment continues at all participating centers.

Jan 13 2020

Recardio at J.P. Morgan Conference 2020

San Francisco, January 13, 2020 – Recardio Inc., a clinical-stage life science company focusing on therapies for cardiovascular diseases, was participating in the 38^th Annual J.P. Morgan Healthcare Conference in San Francisco.

Dec 13 2019

Closing of Series B Financing Round

San Francisco, December 13th, 2019 – Recardio Inc., a clinical stage life science company developing regenerative therapies for cardiovascular diseases,announced the closing of its Series B financing round.

Nov 06 2019

Recardio’s Digital Platform CardioCare Rolled Out in Europe

San Francisco, November 6th, 2019 – Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its it has rolled out its digital platform CardioCare throughout Europe to support its future clinical development programs in cardiovascular.